Cargando…

Phantom criteria for qualification of brain FDG and amyloid PET across different cameras

BACKGROUND: While fluorodeoxyglucose (FDG) and amyloid PET is valuable for patient management, research, and clinical trial of therapeutics on Alzheimer’s disease, the specific details of the PET scanning method including the PET camera model type influence the image quality, which may further affec...

Descripción completa

Detalles Bibliográficos
Autores principales: Ikari, Yasuhiko, Akamatsu, Go, Nishio, Tomoyuki, Ishii, Kenji, Ito, Kengo, Iwatsubo, Takeshi, Senda, Michio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5052249/
https://www.ncbi.nlm.nih.gov/pubmed/27709546
http://dx.doi.org/10.1186/s40658-016-0159-y
_version_ 1782458197163900928
author Ikari, Yasuhiko
Akamatsu, Go
Nishio, Tomoyuki
Ishii, Kenji
Ito, Kengo
Iwatsubo, Takeshi
Senda, Michio
author_facet Ikari, Yasuhiko
Akamatsu, Go
Nishio, Tomoyuki
Ishii, Kenji
Ito, Kengo
Iwatsubo, Takeshi
Senda, Michio
author_sort Ikari, Yasuhiko
collection PubMed
description BACKGROUND: While fluorodeoxyglucose (FDG) and amyloid PET is valuable for patient management, research, and clinical trial of therapeutics on Alzheimer’s disease, the specific details of the PET scanning method including the PET camera model type influence the image quality, which may further affect the interpretation of images and quantitative capabilities. To make multicenter PET data reliable and to establish PET scanning as a universal diagnostic technique and a verified biomarker, we have proposed phantom test procedures and criteria for optimizing image quality across different PET cameras. RESULTS: As the method, four physical parameters (resolution, gray-white contrast, uniformity, and image noise) were selected as essential to image quality for brain FDG and amyloid PET and were measured with a Hoffman 3D brain phantom and a uniform cylindrical phantom on a total of 12 currently used PET models. The phantom radioactivity and acquisition time were determined based on the standard scanning protocol for each PET drug (FDG, (11)C-PiB, (18)F-florbetapir, and (18)F-flutemetamol). Reconstruction parameters were either determined based on the methods adopted in ADNI, J-ADNI, and other research and clinical trials or optimized based on measured phantom image parameters under various reconstruction conditions. As the result, phantom test criteria were proposed as follows: (i) 8 mm FWHM or better resolution and (ii) gray/white %contrast ≥55 % with the Hoffman 3D brain phantom and (iii) SD of 51 small region of interests (ROIs) ≤0.0249 (equivalent to 5 % variation) for uniformity and (iv) image noise (SD/mean) ≤15 % for a large ROI with the uniform cylindrical phantom. These criteria provided image quality conforming to those multicenter clinical studies and were also achievable with most of the PET cameras that are currently used. CONCLUSIONS: The proposed phantom test criteria facilitate standardization and qualification of brain FDG and amyloid PET images and deserve further evaluation by future multicenter clinical studies.
format Online
Article
Text
id pubmed-5052249
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-50522492016-10-24 Phantom criteria for qualification of brain FDG and amyloid PET across different cameras Ikari, Yasuhiko Akamatsu, Go Nishio, Tomoyuki Ishii, Kenji Ito, Kengo Iwatsubo, Takeshi Senda, Michio EJNMMI Phys Original Research BACKGROUND: While fluorodeoxyglucose (FDG) and amyloid PET is valuable for patient management, research, and clinical trial of therapeutics on Alzheimer’s disease, the specific details of the PET scanning method including the PET camera model type influence the image quality, which may further affect the interpretation of images and quantitative capabilities. To make multicenter PET data reliable and to establish PET scanning as a universal diagnostic technique and a verified biomarker, we have proposed phantom test procedures and criteria for optimizing image quality across different PET cameras. RESULTS: As the method, four physical parameters (resolution, gray-white contrast, uniformity, and image noise) were selected as essential to image quality for brain FDG and amyloid PET and were measured with a Hoffman 3D brain phantom and a uniform cylindrical phantom on a total of 12 currently used PET models. The phantom radioactivity and acquisition time were determined based on the standard scanning protocol for each PET drug (FDG, (11)C-PiB, (18)F-florbetapir, and (18)F-flutemetamol). Reconstruction parameters were either determined based on the methods adopted in ADNI, J-ADNI, and other research and clinical trials or optimized based on measured phantom image parameters under various reconstruction conditions. As the result, phantom test criteria were proposed as follows: (i) 8 mm FWHM or better resolution and (ii) gray/white %contrast ≥55 % with the Hoffman 3D brain phantom and (iii) SD of 51 small region of interests (ROIs) ≤0.0249 (equivalent to 5 % variation) for uniformity and (iv) image noise (SD/mean) ≤15 % for a large ROI with the uniform cylindrical phantom. These criteria provided image quality conforming to those multicenter clinical studies and were also achievable with most of the PET cameras that are currently used. CONCLUSIONS: The proposed phantom test criteria facilitate standardization and qualification of brain FDG and amyloid PET images and deserve further evaluation by future multicenter clinical studies. Springer International Publishing 2016-10-06 /pmc/articles/PMC5052249/ /pubmed/27709546 http://dx.doi.org/10.1186/s40658-016-0159-y Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Research
Ikari, Yasuhiko
Akamatsu, Go
Nishio, Tomoyuki
Ishii, Kenji
Ito, Kengo
Iwatsubo, Takeshi
Senda, Michio
Phantom criteria for qualification of brain FDG and amyloid PET across different cameras
title Phantom criteria for qualification of brain FDG and amyloid PET across different cameras
title_full Phantom criteria for qualification of brain FDG and amyloid PET across different cameras
title_fullStr Phantom criteria for qualification of brain FDG and amyloid PET across different cameras
title_full_unstemmed Phantom criteria for qualification of brain FDG and amyloid PET across different cameras
title_short Phantom criteria for qualification of brain FDG and amyloid PET across different cameras
title_sort phantom criteria for qualification of brain fdg and amyloid pet across different cameras
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5052249/
https://www.ncbi.nlm.nih.gov/pubmed/27709546
http://dx.doi.org/10.1186/s40658-016-0159-y
work_keys_str_mv AT ikariyasuhiko phantomcriteriaforqualificationofbrainfdgandamyloidpetacrossdifferentcameras
AT akamatsugo phantomcriteriaforqualificationofbrainfdgandamyloidpetacrossdifferentcameras
AT nishiotomoyuki phantomcriteriaforqualificationofbrainfdgandamyloidpetacrossdifferentcameras
AT ishiikenji phantomcriteriaforqualificationofbrainfdgandamyloidpetacrossdifferentcameras
AT itokengo phantomcriteriaforqualificationofbrainfdgandamyloidpetacrossdifferentcameras
AT iwatsubotakeshi phantomcriteriaforqualificationofbrainfdgandamyloidpetacrossdifferentcameras
AT sendamichio phantomcriteriaforqualificationofbrainfdgandamyloidpetacrossdifferentcameras